We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
1
33.3%
Enrolling By Invitation
Recruiting
No approval data available
• Octave Bioscience's Multiple Sclerosis Disease Activity (MSDA) Test has demonstrated significant impact on clinical decision-making, influencing nearly 60% of MS management cases in a real-world study. • The multi-protein biomarker assay, which measures 18 proteins to assess MS disease activity, has received New York State CLEP certification, making it available in all 50 states. • Study findings show the MSDA Test provides objective data that supports treatment decisions, with nearly 1 in 5 test results leading clinicians to adjust MS management strategies.
